Evidence map›Paper›PMID 34423393›Full record

ArticleJournal of physiology and biochemistry2022

Adiponectin overexpression in C2C12 myocytes increases lipid oxidation and myofiber transition.

Marta Lopez-Yus, Rebeca Lopez-Perez, Maria Pilar Garcia-Sobreviela, Raquel Del Moral-Bergos, Silvia Lorente-Cebrian, Jose M Arbones-Mainar

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of physiology and biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Adiponectin, May Be a Potential Protective Factor for Obesity-Related Osteoarthritis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Marta Lopez-YusAdipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, Instituto Aragones de Ciencias de La Salud (IACS), Instituto de Investigación Sanitaria (IIS)-Aragón, Isabel la Católica, 1-3, 50009, Zaragoza, Spain.
Rebeca Lopez-PerezAdipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, Instituto Aragones de Ciencias de La Salud (IACS), Instituto de Investigación Sanitaria (IIS)-Aragón, Isabel la Católica, 1-3, 50009, Zaragoza, Spain.
Maria Pilar Garcia-SobrevielaAdipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, Instituto Aragones de Ciencias de La Salud (IACS), Instituto de Investigación Sanitaria (IIS)-Aragón, Isabel la Católica, 1-3, 50009, Zaragoza, Spain.
Raquel Del Moral-BergosAdipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, Instituto Aragones de Ciencias de La Salud (IACS), Instituto de Investigación Sanitaria (IIS)-Aragón, Isabel la Católica, 1-3, 50009, Zaragoza, Spain.
Silvia Lorente-CebrianAdipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, Instituto Aragones de Ciencias de La Salud (IACS), Instituto de Investigación Sanitaria (IIS)-Aragón, Isabel la Católica, 1-3, 50009, Zaragoza, Spain.
Jose M Arbones-MainarAdipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, Instituto Aragones de Ciencias de La Salud (IACS), Instituto de Investigación Sanitaria (IIS)-Aragón, Isabel la Católica, 1-3, 50009, Zaragoza, Spain. jmarbones.iacs@aragon.es.ORCID http://orcid.org/0000-0002-8982-3737
Instituto de Investigación Sanitaria Aragón · ESInstituto de Salud Carlos III · ESUniversidad de Zaragoza · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic syndrome and obesity have detrimental effects on the metabolic function of the skeletal muscle. Mounting evidence indicates that patients with those conditions may present an increased ratio of glycolytic to oxidative fibers associated with a decrease in oxidative capacity. In this regard, adiponectin, a hormone mainly secreted by adipocytes that regulates glucose and lipid metabolism, has emerged as a myokine that could play an important role in this process. We aimed to investigate whether adiponectin overexpression in skeletal muscle might be a local protective mechanism, favoring fatty acid utilization. To that end, we generated an in vitro model of myocytes with upregulated endogenous adiponectin using a lentiviral carrier. We demonstrated that the adiponectin-transduced myocytes were able to produce and secrete fully functional adiponectin complexes. Adiponectin overexpression remarkably upregulated the mRNA level of myogenic regulatory factors as well as genes implicated in lipolysis (HSL, ATGL) and cellular and mitochondrial fatty acid transport (LPL, CD36, CPT1B). This was accompanied by increased isoproterenol-induced lipolysis and β-oxidation and reduced lipogenesis, whereas insulin-stimulated glucose uptake was unaltered in transduced myocytes. Lastly, the relative expression of the more glycolytic myofibers (MyHC IIb) compared to the more oxidative ones (MyHC I) was notably reduced. Our results showed that the released adiponectin acted in an autocrine/paracrine manner, increasing lipid oxidation in myocytes and leading to a transition of myofibers from the glycolytic to the oxidative type. In conclusion, muscle adiponectin overexpression might be a way to relieve muscle diseases caused by oxidative muscle fiber deficiency.

Indexed as

AdiponectinLipid MetabolismMuscle CellsAnimalsFatty AcidsLipolysisMiceMuscle, SkeletalAdiponectinFatty AcidsAdipokineLentivirusMuscleMyopathy

Identifiers

PMID34423393
OpenAlexW3193497667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.